{"id":2625,"date":"2020-08-31T11:20:19","date_gmt":"2020-08-31T11:20:19","guid":{"rendered":"http:\/\/sparxbio.com\/?p=2625"},"modified":"2020-08-31T16:31:10","modified_gmt":"2020-08-31T16:31:10","slug":"former-eli-lilly-veteran-dr-victor-wroblewski-joins-sparx-therapeutics-as-a-senior-vp-and-head-of-biology","status":"publish","type":"post","link":"\/?p=2625","title":{"rendered":"Former Eli Lilly veteran Dr. Victor Wroblewski joins Sparx Therapeutics as a Senior VP and Head of Biology"},"content":{"rendered":"<p><strong>Chicago\uff0cUSA<br \/>\nSeptember 1, 2020<\/strong><\/p>\n<p><strong>Sparx Therapeutics<\/strong>, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr. Victor Wroblewski, a former Eli Lilly veteran, as a Senior VP and Head of Biology. Dr. Victor Wroblewski brings in decades of deep knowledge and experience in antibody drug development.<\/p>\n<p>\u201cWe are very proud to welcome Dr. Wroblewski to Sparx,\u201d said Dr. Guidong Zhu, CEO and founder of Sparx. \u201cVictor is a highly accomplished drug hunter with unmatched experience and skills in antibody drug characterization and optimization. Few people in the world have the acumen and instinct that Victor has in developing the most promising biological drug candidates. Multi-specific antibody technologies hold great promises in unlocking the complex codes of solid tumor, but getting through this largely unexplored jungle isn\u2019t for the fainthearted. A seasoned veteran like Victor makes all the differences in the world.\u201d<\/p>\n<p>\u201cMetastatic solid cancer remains the holy grail in cancer drug discovery,\u201d said Dr. Wroblewski, \u201cbut lack of high-quality tumor specific antigens hampered the progress. Multi-specific antibody and ADC may significantly expand the antigen pool for solid cancer drug discovery. Sparx\u2019s multi-pillar antibody discovery and optimization platform, especially the SMARTOPTM and LEMMAbTM technologies, could identify first-in-class and best-in-class cancer drugs with industry-leading efficiency. I was also impressed by Sparx\u2019s upstream target ID and downstream CMC capabilities.\u201d<\/p>\n<p>Dr. Victor Wroblewski is a well-known industrial scientist with three decades of experience in antibody drug R&amp;D. He was a distinguished research fellow at Eli Lilly &amp; Co, leading integrated efforts to optimize the biological and pharmaceutical properties of complex biologics and a research director at Indiana Biotechnology Research Institute. Victor contributed to the commercial launch of several biologics drug products at Lilly including Erbitux\u00ae, TaltzTM, Latruvo\u00ae, Trulicity\u00ae, Humalog\u00ae, and humatrope\u00ae. For his outstanding accomplishment, Victor received several awards including \u201cChange the World\u201d recognition (Lilly Oncology, 2011) and President\u2019s Scientific Recognition Award (Lilly Research Laboratories, 2010).<\/p>\n<h4 style=\"background: #0000aa; color: #fff; padding: 5px 10px; display: inline-block; margin: 20px 0 0 0; font-weight: bold;\">About Sparx Therapeutics, Inc.<\/h4>\n<p>Sparx Therapeutics is an integrated biopharmaceutical company based in Chicago. Since its incorporation in 2018, Sparx has built a sophisticated multi-specific antibody drug discovery platform and identified 6 IND-ready drug candidates. The SMARTOP\u2122 and LEMMA\u2122 technologies allow the expedite discovery of multi-functional biologics with favorable drug-like properties. An AI-based target identification algorithm feeds a constant stream of novel targets and target pairs. Sparx also constructed an in-house biologics cGMP facility in its Chicago headquarter to produce clinical and commercial biologics drug substances. For further information, please visit www.sparxbio.com<\/p>\n<p><strong>Contact<\/strong><br \/>\nSparx Theraeputics<br \/>\nPublic Relation<br \/>\nTel: +1 847 979 0886 ext. 800<br \/>\nInternet: <a href=\"mailto:PR@sparxbio.com\">PR@sparxbio.com<\/a><\/p>\n<p>Media Inquiries<br \/>\n<a href=\"mailto:PR@sparxbio.com\">PR@sparxbio.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chicago\uff0cUSA September 1, 2020 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr. Victor Wroblewski, a former Eli Lilly veteran, as a Senior VP and Head of Biology. Dr. Victor Wroblewski brings in decades of deep knowledge and experience in antibody drug development. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[40],"tags":[],"_links":{"self":[{"href":"\/index.php?rest_route=\/wp\/v2\/posts\/2625"}],"collection":[{"href":"\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2625"}],"version-history":[{"count":2,"href":"\/index.php?rest_route=\/wp\/v2\/posts\/2625\/revisions"}],"predecessor-version":[{"id":2636,"href":"\/index.php?rest_route=\/wp\/v2\/posts\/2625\/revisions\/2636"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/index.php?rest_route=\/wp\/v2\/media\/2626"}],"wp:attachment":[{"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2625"},{"taxonomy":"post_tag","embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}